| Dr Teresa Ann Fama, MD | |
|
130 Fisher Road, Mob-b Suite 2-3, Berlin, VT 05602-9522 | |
| (802) 225-1750 | |
| (802) 225-1733 |
| Full Name | Dr Teresa Ann Fama |
|---|---|
| Gender | Female |
| Speciality | Rheumatology |
| Experience | 22 Years |
| Location | 130 Fisher Road, Berlin, Vermont |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376660977 | NPI | - | NPPES |
| 1014060 | Medicaid | VT |
| Facility Name | Location | Facility Type |
|---|---|---|
| Central Vermont Medical Center | Barre, VT | Hospital |
| Northeastern Vermont Regional Hospital | Saint johnsbury, VT | Hospital |
| Gifford Medical Center | Randolph, VT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Central Vermont Medical Center Inc | 9335138817 | 204 |
News Archive
Women are more likely to develop anxiety and depression after a heart attack (myocardial infarction; MI) than men, according to research presented at Acute Cardiovascular Care 2014 by Professor Pranas Serpytis from Lithuania.
An intensive, comprehensive, long-term secondary prevention program lasting up to three years after cardiac rehabilitation appears to reduce the risk of a second non-fatal heart attack and other cardiovascular events, according to a report in the November 10 issue of Archives of Internal Medicine , one of the JAMA/Archives journals.
GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved raxibacumab for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.
Research shows that, nationally, states are facing more than $550 billion in unfunded liabilities associated with health care and other non-pension benefits for retired state employees, a situation many states are now struggling to fix. New research from North Carolina State University has identified a number of trends that are consistent among those states with the biggest funding problems - information that may help states find a solution to the funding shortfall.
Meda announced today positive results from a Phase III clinical trial of Dymista, a novel formulation of azelastine hydrochloride and fluticasone propionate, in patients with seasonal allergic rhinitis.
› Verified 2 days ago
| Entity Name | Central Vermont Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023028784 PECOS PAC ID: 9335138817 Enrollment ID: O20051220000393 |
News Archive
Women are more likely to develop anxiety and depression after a heart attack (myocardial infarction; MI) than men, according to research presented at Acute Cardiovascular Care 2014 by Professor Pranas Serpytis from Lithuania.
An intensive, comprehensive, long-term secondary prevention program lasting up to three years after cardiac rehabilitation appears to reduce the risk of a second non-fatal heart attack and other cardiovascular events, according to a report in the November 10 issue of Archives of Internal Medicine , one of the JAMA/Archives journals.
GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved raxibacumab for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.
Research shows that, nationally, states are facing more than $550 billion in unfunded liabilities associated with health care and other non-pension benefits for retired state employees, a situation many states are now struggling to fix. New research from North Carolina State University has identified a number of trends that are consistent among those states with the biggest funding problems - information that may help states find a solution to the funding shortfall.
Meda announced today positive results from a Phase III clinical trial of Dymista, a novel formulation of azelastine hydrochloride and fluticasone propionate, in patients with seasonal allergic rhinitis.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Teresa Ann Fama, MD Po Box 547, Central Vermont Medical Center Inc-finance Dept, Barre, VT 05641-0547 Ph: (802) 225-1750 | Dr Teresa Ann Fama, MD 130 Fisher Road, Mob-b Suite 2-3, Berlin, VT 05602-9522 Ph: (802) 225-1750 |
News Archive
Women are more likely to develop anxiety and depression after a heart attack (myocardial infarction; MI) than men, according to research presented at Acute Cardiovascular Care 2014 by Professor Pranas Serpytis from Lithuania.
An intensive, comprehensive, long-term secondary prevention program lasting up to three years after cardiac rehabilitation appears to reduce the risk of a second non-fatal heart attack and other cardiovascular events, according to a report in the November 10 issue of Archives of Internal Medicine , one of the JAMA/Archives journals.
GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved raxibacumab for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.
Research shows that, nationally, states are facing more than $550 billion in unfunded liabilities associated with health care and other non-pension benefits for retired state employees, a situation many states are now struggling to fix. New research from North Carolina State University has identified a number of trends that are consistent among those states with the biggest funding problems - information that may help states find a solution to the funding shortfall.
Meda announced today positive results from a Phase III clinical trial of Dymista, a novel formulation of azelastine hydrochloride and fluticasone propionate, in patients with seasonal allergic rhinitis.
› Verified 2 days ago
Laura Allen Felsted, DO Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 130 Fisher Rd Ste 3, Mountainview Medical, Berlin, VT 05602 Phone: 802-225-5400 Fax: 802-225-5401 | |
Devika Singh, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 130 Fisher Rd, Mob-b Suite 3, Berlin, VT 05602 Phone: 802-225-5400 Fax: 802-225-5401 | |
Brett Erdreich, Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 130 Fisher Rd, Berlin, VT 05602 Phone: 802-371-4100 | |
Dr. Joachim Georg Mueller, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 130 Fisher Rd, Cardiology Mob-a Suite 2-1, Berlin, VT 05602 Phone: 802-225-5660 Fax: 802-229-9533 | |
Sarah E Swift, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 130 Fisher Rd, Hospitalist Program, Berlin, VT 05602 Phone: 802-225-1743 Fax: 802-225-1745 | |
Hannah Swayze-quinn, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 130 Fisher Rd, Hospitalist Program, Berlin, VT 05602 Phone: 802-225-1743 Fax: 802-225-1745 | |
Peter Alan Redford, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 130 Fisher Rd, Hospitalist Program, Berlin, VT 05602 Phone: 802-225-1743 Fax: 802-225-1745 |